Elevance Health (NYSE:ELV - Get Free Report) is anticipated to announce its earnings results before the market opens on Tuesday, April 22nd. Analysts expect the company to announce earnings of $10.60 per share and revenue of $46.26 billion for the quarter. Elevance Health has set its FY 2025 guidance at 34.150-34.850 EPS.Individual that wish to register for the company's earnings conference call can do so using this link.
Elevance Health (NYSE:ELV - Get Free Report) last released its quarterly earnings data on Thursday, January 23rd. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.80 by $0.04. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. On average, analysts expect Elevance Health to post $34 EPS for the current fiscal year and $39 EPS for the next fiscal year.
Elevance Health Price Performance
NYSE:ELV traded down $10.60 during trading hours on Friday, reaching $424.44. The company had a trading volume of 3,569,359 shares, compared to its average volume of 1,444,131. The firm has a market capitalization of $96.09 billion, a PE ratio of 16.57, a PEG ratio of 1.18 and a beta of 0.77. The stock has a 50-day moving average of $416.77 and a two-hundred day moving average of $410.42. Elevance Health has a one year low of $362.21 and a one year high of $567.26. The company has a quick ratio of 1.50, a current ratio of 1.45 and a debt-to-equity ratio of 0.71.
Elevance Health Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, March 25th. Stockholders of record on Monday, March 10th were issued a $1.71 dividend. This is a positive change from Elevance Health's previous quarterly dividend of $1.63. The ex-dividend date of this dividend was Monday, March 10th. This represents a $6.84 annualized dividend and a dividend yield of 1.61%. Elevance Health's dividend payout ratio is presently 26.71%.
Wall Street Analyst Weigh In
Several analysts have weighed in on ELV shares. Robert W. Baird reaffirmed a "neutral" rating and set a $529.00 price objective (down from $625.00) on shares of Elevance Health in a research note on Tuesday. Argus upgraded Elevance Health from a "hold" rating to a "buy" rating and set a $450.00 price target on the stock in a research report on Monday, March 17th. Wells Fargo & Company reduced their price objective on Elevance Health from $483.00 to $478.00 and set an "overweight" rating on the stock in a research note on Tuesday, January 28th. Mizuho lifted their price target on Elevance Health from $455.00 to $505.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Finally, StockNews.com raised shares of Elevance Health from a "hold" rating to a "buy" rating in a report on Thursday, March 20th. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, Elevance Health currently has an average rating of "Moderate Buy" and a consensus price target of $514.41.
View Our Latest Stock Report on ELV
Insider Transactions at Elevance Health
In related news, CAO Ronald W. Penczek sold 443 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $415.13, for a total value of $183,902.59. Following the transaction, the chief accounting officer now directly owns 1,847 shares in the company, valued at approximately $766,745.11. This represents a 19.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of Elevance Health stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $396.30, for a total transaction of $1,388,635.20. Following the completion of the sale, the executive vice president now owns 10,116 shares of the company's stock, valued at $4,008,970.80. This trade represents a 25.73 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.29% of the company's stock.
Elevance Health Company Profile
(
Get Free Report)
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
Further Reading
Before you consider Elevance Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.
While Elevance Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
